Cardiac Power, Inc. to Present at Medtech Insight's ``Investment In Innovation'' Conference.

IRVINE, Calif. -- Cardiac Power Inc.:

--Cardiac Power, Inc. has announced that it will be presenting at 9:00 AM, Feb. 11th at Medtech Insight's Prestigious "Investment In Innovation (In3): A Preview of Early-Stage Medical Technology Companies" Conference, taking place February 10-11, 2005 at the Hyatt Regency Irvine in Irvine, California.

Cardiac Power Inc.(TM) (CPI), founded by David Melvin, M.D., Ph.D., has developed and patented a heart assist technology to treat Congestive Heart Failure (CHF) that could solve the primary problem all current devices are encountering: immunobiologic response which can cause sepsis and stroke. CPI has developed a heart-assist device, RePower(TM), which does not interface with circulating blood and could become a safer and more cost-effective alternative to heart transplants, ventricular assist devices, and artificial hearts. The opportunity for RePower(TM) exceeds 200,000 patients a year, providing a worldwide market potential over $10 Billion.

Economic impact studies paint a staggering picture. CHF is the single biggest drain on the Medicare system today and remains the most expensive healthcare problem in the U.S. and other developed countries. In the United States, hospitalization for CHF totals more that 6.5 million days, and the annual costs are estimated at $30-$40 billion, over 5% of total healthcare costs in America.

During the past several years there has been a dramatic increase in the use of heart assist devices such as left ventricular assist devices, LVADs. Likewise, there has been an increase in research to determine what causes, and how to prevent, the serious side effects, sepsis and stroke, seen in patients that have had these devices implanted. Silviu Itescu, M.D., Columbia University, has documented that the blood material interface creates an immunobiologic response which causes a cascade of events which can ultimately lead to stroke and, or, sepsis.

The RePower(TM) cardiac assist system is a patented (eleven issued) technology to enable a weakened heart to pump a normal amount of blood. The underlying goal of RePower(TM) is to fix the primary problem of failing hearts -- insufficient pumping power -- without introducing additional complications from artificial materials interfacing with blood. RePower(TM) accomplishes this emcompassing the heart and creating a contraction similar to open heart massage.

Cardiac Power Inc. has developed a strong intellectual property position through patents and licensing agreements. Issued U.S. patents, allowed international patents and numerous continuations, cover RePower(TM)'s technology. Because this is a seminal invention, the breadth of claims is significant. The RePower(TM) cardiac assist system is a new, patented way to make a weakened heart pump a normal amount of blood. Unlike existing heart assist devices, it eliminates the source of strokes and sepsis common to all, by not interfacing with circulating blood. The company expects this difference to lead to dramatic improvements in clinical and economic outcomes.

Now a division of Windhover Information Inc., Medtech Insight is the leading provider of business information and market intelligence for the medical technology marketplace. To register for In3 Irvine or for more information on Medtech Insight, please call Scott Pantel at 949-219-0150 or 888-290-2225 toll-free in the U.S., e-mail [e-mail], or visit www.medtechinsight.com.